Find Granulomatosis with Polyangiitis Clinical Trials Near You
ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study With Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Status: Recruiting
Location: See all (47) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Healthy Volunteers: f
View:
• 1\. Provision of signed and dated written ICF.
• 2\. Participants completing minimum required OLE period of a parent study and judged by the Investigator to benefit from continued treatment.
• 3\. Participants must agree to follow the contraception requirements as per their respective parent protocols from study inclusion up to 12 weeks after the last dose of study treatment.
• 4\. Participants without childbearing potential at enrolment must agree to start appropriate contraception if childbearing potential develops during the study and up to 12 weeks after the last dose of study treatment.
• 5\. Participants who are unable to access commercially available benralizumab and clinically indicated for continuation.
Locations
United States
Colorado
Research Site
NOT_YET_RECRUITING
Aurora
Maryland
Research Site
NOT_YET_RECRUITING
Bethesda
Michigan
Research Site
NOT_YET_RECRUITING
Ann Arbor
North Carolina
Research Site
NOT_YET_RECRUITING
Durham
New Jersey
Research Site
NOT_YET_RECRUITING
Northfield
New York
Research Site
NOT_YET_RECRUITING
The Bronx
Ohio
Research Site
NOT_YET_RECRUITING
Cleveland
Utah
Research Site
NOT_YET_RECRUITING
Salt Lake City
Other Locations
Argentina
Research Site
RECRUITING
Buenos Aires
Research Site
RECRUITING
Florida
Research Site
NOT_YET_RECRUITING
Lobos
Research Site
RECRUITING
Mar Del Plata
Research Site
RECRUITING
Mendoza
Research Site
RECRUITING
Mendoza
Research Site
NOT_YET_RECRUITING
Rosario
Research Site
RECRUITING
Rosario
Research Site
NOT_YET_RECRUITING
San Juan Bautista
Austria
Research Site
NOT_YET_RECRUITING
Innsbruck
Belgium
Research Site
RECRUITING
Brussels
Research Site
NOT_YET_RECRUITING
Edegem
Canada
Research Site
NOT_YET_RECRUITING
Calgary
Research Site
NOT_YET_RECRUITING
Hamilton
Research Site
NOT_YET_RECRUITING
Toronto
Research Site
RECRUITING
Toronto
Research Site
RECRUITING
Toronto
France
Research Site
NOT_YET_RECRUITING
Bron
Research Site
RECRUITING
Marseille
Research Site
RECRUITING
Montpellier
Research Site
RECRUITING
Nantes
Research Site
RECRUITING
Paris
Research Site
RECRUITING
Paris
Research Site
RECRUITING
Pessac
Research Site
RECRUITING
Suresnes
India
Research Site
WITHDRAWN
Ahmedabad
Research Site
NOT_YET_RECRUITING
Ajmer
Israel
Research Site
RECRUITING
Haifa
Research Site
NOT_YET_RECRUITING
Holon
Research Site
NOT_YET_RECRUITING
Petah Tikva
Italy
Research Site
WITHDRAWN
Roma
Netherlands
Research Site
NOT_YET_RECRUITING
Rotterdam
Poland
Research Site
NOT_YET_RECRUITING
Chęciny
Research Site
NOT_YET_RECRUITING
Gdansk
Research Site
WITHDRAWN
Lodz
Research Site
NOT_YET_RECRUITING
Lodz
Republic of Korea
Research Site
RECRUITING
Incheon
Turkey
Research Site
NOT_YET_RECRUITING
Istanbul
United Kingdom
Research Site
RECRUITING
London
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date:2026-07-24
Estimated Completion Date:2029-12-27
Participants
Target number of participants:230
Treatments
Experimental: Benralizumab arm
Benralizumab will be administrated as an subcutaneous injection at a frequency in line with that received in the parent study.